American Association of Immunologists

Table II.

Lymph node T cells and thymocytes from CD8mg transgenic, class II MHC-deficient mice^a

Genotype	No. of Cells/ Thymus (× 10⁶)	Percent Lymph Node T Cells			Percent Total Thymocytes			Percent HSA-Thymocytes		4:8 Ratio	n
Genotype	No. of Cells/ Thymus (× 10⁶)			CD4⁺8.2⁻ TCR⁺	CD4⁻8.2⁺ TCR⁺	TCR⁺ CD4⁺8.2⁻	TCR⁺ CD4⁻8.2⁺	TCR⁺ CD4⁺8.2⁻	TCR⁺ CD4⁻8.2⁻	4:8 Ratio	n
Nontransgenic		35 ± 2.0	21 ± 1.1					1.7	8
CD8mg transgenic		40 ± 1.5	20 ± 0.6					2.0	9
Class II⁻		1.6 ± 0.1	50 ± 1.8					0.033	10
Class II⁻/CD8mg transgenic		2.8 ± 0.2	50 ± 1.2					0.046	7
Nontransgenic	224 ± 16			7.0 ± 0.2	5.2 ± 0.3	66 ± 0.5	20 ± 1.0	3.3	8
CD8mg transgenic	174 ± 11			8.0 ± 0.5	6.2 ± 0.5	61 ± 0.9	25 ± 0.9	2.4	9
Class II⁻	197 ± 15			1.1 ± 0.2	6.8 ± 0.3	5.0 ± 0.2	71 ± 2.0	0.068	10
Class II⁻/CD8mg transgenic	209 ± 18			1.6 ± 0.1	7.0 ± 0.6	7.1 ± 0.4	74 ± 1.5	0.096	7

Genotype	No. of Cells/ Thymus (× 10⁶)	Percent Lymph Node T Cells			Percent Total Thymocytes			Percent HSA-Thymocytes		4:8 Ratio	n
Genotype	No. of Cells/ Thymus (× 10⁶)			CD4⁺8.2⁻ TCR⁺	CD4⁻8.2⁺ TCR⁺	TCR⁺ CD4⁺8.2⁻	TCR⁺ CD4⁻8.2⁺	TCR⁺ CD4⁺8.2⁻	TCR⁺ CD4⁻8.2⁻	4:8 Ratio	n
Nontransgenic		35 ± 2.0	21 ± 1.1					1.7	8
CD8mg transgenic		40 ± 1.5	20 ± 0.6					2.0	9
Class II⁻		1.6 ± 0.1	50 ± 1.8					0.033	10
Class II⁻/CD8mg transgenic		2.8 ± 0.2	50 ± 1.2					0.046	7
Nontransgenic	224 ± 16			7.0 ± 0.2	5.2 ± 0.3	66 ± 0.5	20 ± 1.0	3.3	8
CD8mg transgenic	174 ± 11			8.0 ± 0.5	6.2 ± 0.5	61 ± 0.9	25 ± 0.9	2.4	9
Class II⁻	197 ± 15			1.1 ± 0.2	6.8 ± 0.3	5.0 ± 0.2	71 ± 2.0	0.068	10
Class II⁻/CD8mg transgenic	209 ± 18			1.6 ± 0.1	7.0 ± 0.6	7.1 ± 0.4	74 ± 1.5	0.096	7

Total thymocytes, mature thymocytes (HSA depleted), or lymph node T cells were stained with Abs against TCR, CD4, and CD8.2 (endogenous CD8) as described in Materials and Methods. Average values and SDs are given, and n is the number of mice of each genotype analyzed.

View Large

This Feature Is Available To Subscribers Only